These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37092904)

  • 21. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
    Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
    Chen Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
    Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
    Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
    Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
    Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
    Ueberroth BE; Jones JC; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers - current evidence and future directions.
    Lam RCT; Johnson D; Lam G; Li MLY; Wong JWL; Lam WKJ; Chan KCA; Ma B
    Front Oncol; 2022; 12():970242. PubMed ID: 36248993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
    Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
    Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.
    Egyud M; Tejani M; Pennathur A; Luketich J; Sridhar P; Yamada E; Ståhlberg A; Filges S; Krzyzanowski P; Jackson J; Kalatskaya I; Jiao W; Nielsen G; Zhou Z; Litle V; Stein L; Godfrey T
    Ann Thorac Surg; 2019 Aug; 108(2):343-349. PubMed ID: 31059681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
    Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
    Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumor DNA in Hodgkin lymphoma.
    Maco M; Kupcova K; Herman V; Ondeckova I; Kozak T; Mocikova H; Havranek O;
    Ann Hematol; 2022 Nov; 101(11):2393-2403. PubMed ID: 36074181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
    Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
    Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
    Earland N; Chen K; Semenkovich NP; Chauhan PS; Zevallos JP; Chaudhuri AA
    Semin Radiat Oncol; 2023 Jul; 33(3):262-278. PubMed ID: 37331781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.